HC Wainwright & Co. Reiterates Buy on C4 Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates C4 Therapeutics (NASDAQ:CCCC) with a Buy and maintains $35 price target.
JP Morgan Downgrades C4 Therapeutics to Underweight, Lowers Price Target to $5
JP Morgan analyst Eric Joseph downgrades C4 Therapeutics (NASDAQ:CCCC) from Neutral to Underweight and lowers the price target from $15 to $5.
C4 Therapeutics Reports FY22 Revenue $31.1M Vs $45.8M YoY; FY22 EPS $(2.62) Vs $(1.82) YoY
FULL YEAR 2022 FINANCIAL RESULTS
Revenue: Total revenue for the year ended December 31, 2022 was $31.1 million, compared to $45.8 million for the year ended December 31, 2021. Total revenue reflects
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday’s Mid-Day Session
Gainers
Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08.
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving.
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers
Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.